Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Starting dose final guidance

Executive Summary

FDA final guidance on "FDL-1Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers," released July 22, provides an algorithm by which maximum recommended starting dose (MRSD) can be selected for first-in-human clinical trials. Document generally reflects draft version. The process outlined for calculating MRSD uses administered doses, observed toxicities and an algorithmic approach, although "an alternative approach could be proposed that places primary emphasis on animal pharmacokinetics and modeling rather than dose," FDA says. Merck and Bristol-Myers Squibb had requested that the process include alternate methods for deriving MRSD rather than a single approach (1"The Pink Sheet" May 12, 2003, p. 23)...

You may also be interested in...



Starting Dose Guidance Should Allow Alternate Methods – Merck, Bristol

FDA should expand on alternative methods for selecting a starting dose in clinical trials in addition to the algorithm recommended in a draft guidance, Merck and Bristol-Myers Squibb say in comments

Health And Wellness Trademark Review 2 March, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations

Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel